Get In Touch

Hyperlipidemia, also called hyperlipoproteinemia, is a lipid disorder caused due to the increase in levels of lipids (fats) in the bloodstream. It is caused due to improper lipid metabolism or a disorder in the synthesis and degradation of plasma lipoproteins or plasma lipid transport. Hyperlipidemia means abnormally high levels of lipids (fats) in the blood. These lipids include cholesterol and triglycerides. The primary biological function of these lipids is the storage of energy. However, abnormal lipid metabolism results into metabolic syndrome such as obesity, diabetes, hypertension, and hyperlipidemia. Deposition of fats and cholesterol along the walls of the arteries leads to atherosclerosis. Furthermore, high levels of serum total cholesterol (TC), very low density lipoprotein (VLDL), low density lipoproteins (LDL), and decrease in high density lipoprotein (HDL) are major risk factors for chronic degenerative disease and coronary heart diseases.

Antihyperlipidemic drugs or agents help reduce lipid levels in the blood. A few antihyperlipidemic agents reduce triglyceride levels, some help reduce low-density lipoprotein cholesterol levels, and some help raise the high-density lipoprotein cholesterol. Primary and secondary symptoms of coronary heart disease are prevented by reducing the low-density lipoprotein cholesterol. Antihyperlipidemic agents function in a number of ways such as they inhibit cholesterol absorption in the intestine and also prevent cholesterol synthesis. Moreover, they sequester bile acids in the intestine and alter relative levels and patterns of different plasma lipoproteins.

The global antihyperlipidemic drugs market is anticipated to expand during the forecast period due to the increase in hyperlipidemia cases. The primary cause of hyperlipidemia is lifestyle habits or medical conditions. Obesity, smoking, and lack of exercise are lifestyle habits that are expected to lead to hyperlipidemia. Medical conditions that are likley to result in hyperlipidemia are kidney disease, diabetes, pregnancy, etc. The global antihyperlipidemic drugs market is expected to expand due to the increase in the elderly population and incidence of cardiovascular diseases. According to the European Society of Cardiology (ESC) there are more than 11 million new cases of cardiovascular diseases in Europe and more than six million new cases in the European Union. Moreover, according to the report by faculties of the Department of Nutrition and Health Sciences, University Putra Malaysia, by 2020, cardiovascular diseases are expected to account for seven out of every 10 deaths in developing countries.

The global antihyperlipidemic drugs market can be segmented based on class, distribution, channels, and region. Based on class, the global antihyperlipidemic drugs market can be segregated into bile acid sequesters, cholesterol absorption inhibitors, fibrates (fibric acid derivatives), miscellaneous antihyperlipidemic agents, PCSK9 inhibitors, and statins. These classes of antihyperlipidemic drugs differ in their mechanism of action and also in the type of lipid reduction and the magnitude of the reduction. Statins are the most common group of antihyperlipidemic drugs, which function in lowering the cholesterol levels by interrupting the cholesterol biosynthetic pathway. The fibrate class of antihyperlipidemic drugs decrease fatty acid and triglyceride levels by stimulating the peroxisomal b-oxidation pathway. Based on distribution channel, the global antihyperlipidemic drugs market can be segmented into hospital pharmacies, retail stores, and online retailers. The hospital pharmacies segment accounts for a prominent share of the global antihyperlipidemic drugs market.

In terms of geography, the market is segmented into Europe, Latin America, Asia Pacific, North America, and Middle East & Africa. North America dominates the antihyperlipidemic drugs market in terms of revenue and is anticipated to dominate during the forecast period. Rising prevalence of vascular diseases and number of amputations in the region are likely to augment the antihyperlipidemic drugs market in North America. Expansion of the market in North America can also be attributed to substantial investments in R&D and healthcare expenditure by governments and private players operating in the field of prosthetics in the region. Europe follows North America in terms of share of the global antihyperlipidemic drugs market. This is due to compulsory medical insurance in countries such as Germany and France, high disposable income and high research and development activities in the healthcare sector of the region. The market in Asia Pacific and Middle East & Africa is anticipated to expand at a significant growth rate during the forecast period.

Key players operating in the global antihyperlipidemic drugs market are AstraZeneca plc, Grifols S.A., Pfizer, Inc.,Shire Plc, Biotest AG, Octapharma AG, Kedrion S.p.A., Baxalta Incorporated and Talecris Biotherapeutics, Inc.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Antihyperlipidemic Drugs Market

Pre Book